

Information for Health Care Professionals

Notice – Tiered Biologics Reimbursement Policy

Effective August 15, 2018

- This Notice is being sent to all pharmacies and healthcare providers that prescribe and/or dispense biologics.
- According to the Canadian Institute for Health Information report “*Prescribed Drug Spending in Canada, 2016: Focus on Public Programs*”, biologic drugs represented the class of drugs with the highest proportion of public drug program spending in 2015
- Effective August 15, 2018 Manitoba Health, Seniors and Active Living will be implementing a Tiered Biologics Reimbursement Policy.
- Tier 1 biologic products (for the indications noted) have been determined to be the most cost-effective agents which allows Pharmacare to achieve greater value for its publicly funded drug programs, treat more patients without increasing expenditures, and retain prescriber/patient choice.
- This Policy will ONLY apply to New Patients (biologic naïve) and Existing Patients that have previously been trialed and deemed unresponsive to biologic therapy as follows:
 - New Patients (biologic-naïve);
 - Select product from Tier 1 → Fail → Select second product from Tier 1 → Fail → Select any agent (Tier 1 or Tier 2)
 - Existing Patients (ONLY those that have previously been trialed and deemed unresponsive to biologic therapy)
 - Currently on Tier 1* product → Fail → Select second product from Tier 1 → Fail → Select any agent (Tier 1 or Tier 2)
 - Currently on Tier 2** product → Fail → Select product from Tier 1 → Fail → Select second product from Tier 1 → Fail → Select any agent (Tier 1 or Tier 2)

***NOTE:** *Patients will not be permitted to switch from Inflectra, Brenzys or Erelzi to another infliximab or etanercept product listed in Tier 1 and/or 2 if previously trialed and deemed unresponsive to therapy.*


****NOTE:** *Patients will not be permitted to switch from Remicade or Enbrel to another infliximab or etanercept product listed in Tier 1 if previously trialed and deemed unresponsive to therapy.*

Special Requests (Case-By-Case)


- To request special consideration for coverage on a case-by-case basis outside of this Policy, the clinician may write to the Provincial Drug Programs Review Committee (PDPRC), based upon the unique circumstances of the patient and alternative treatments tried.
- Additional information on the Provincial Drug Programs Review Process and requirements can be found at: <https://www.gov.mb.ca/health/mdbif/docs/edsnotice.pdf>.

Tiered Biologics Reimbursement Policy Flowsheet

New Patients (Biologic-Naïve):



Existing Patients:



**NOTE: Patients will not be permitted to switch from Inflectra, Brenzys or Erelzi to another infliximab or etanercept product listed in Tier 1 and/or 2 if previously trialed and deemed unresponsive to therapy.*

***NOTE: Patients will not be permitted to switch from Remicade or Enbrel to another infliximab or etanercept product listed in Tier 1 if previously trialed and deemed unresponsive to therapy.*

Tier 1							
Product Name	Generic Name	Rheumatoid Arthritis (RA)	Ankylosing Spondylitis (AS)	Plaque Psoriasis (PsO)	Psoriatic Arthritis (PsA)	Crohn's Disease (CD)	Ulcerative Colitis (UC)
Actemra	tocilizumab	X					
Brenzys	etanercept	X	X				
Cimzia	certolizumab pegol	X	X		X		
Cosentyx	secukinumab		X	X	X		
Entyvio	vedolizumab					X	X
Erelzi	etanercept	X	X				
Humira	adalimumab						X
Inflectra	infliximab	X	X	X	X	X	X
Orencia	abatacept	X					
Rituxan	rituximab	X					
Simponi	golimumab	X	X		X		X
Simponi IV	golimumab	X					
Taltz	ixekizumab			X			
Xeljanz	tofacitinib	X					
Tier 2							
Enbrel	etanercept	X	X	X	X		
Humira	adalimumab	X	X	X	X	X	
Kineret	anakinra	X					
Remicade	infliximab	X	X	X	X	X	X
Stelara	ustekinumab			X			

- Prescribing Criteria for all products noted above can be found on the online document: Part 3 Exception Drug Status (EDS) here: <https://www.gov.mb.ca/health/mdbif/docs/edsnotice.pdf>
- For information on Health Canada's review and recommendations, please see: <https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>
- For Common Drug Review's review and recommendations, please see: <https://www.cadth.ca/about-cadth/what-we-do/products-services/cdr/reports>

If your questions are not answered by reviewing this Notice posted at:
<https://www.gov.mb.ca/health/pharmacare/healthprofessionals.html>

Please send an e-mail to PDPInfoAudit@gov.mb.ca

Dermatology (Plaque Psoriasis)

Tier 1	
Cosentyx	(secukinumab)
Inflixtra	(infliximab)
Taltz	(ixekizumab)
Tier 2	
Enbrel	(etanercept)
Humira	(adalimumab)
Remicade	(infliximab)
Stelara	(ustekinumab)

Gastroenterology (Crohn’s Disease)

Tier 1	
Entyvio	(vedolizumab)
Inflixtra	(infliximab)
Tier 2	
Humira	(adalimumab)
Remicade	(infliximab)

Gastroenterology (Ulcerative Colitis)

Tier 1	
Entyvio	(vedolizumab)
Humira	(adalimumab)
Inflixtra	(infliximab)
Simponi	(golimumab)
Tier 2	
Remicade	(infliximab)

Rheumatology (Ankylosing Spondylitis)

Tier 1	
Brenzys	(etanercept)
Cimzia	(certolizumab pegol)
Cosentyx	(secukinumab)
Erelzi	(etanercept)
Inflixtra	(infliximab)
Simponi	(golimumab)
Tier 2	
Enbrel	(etanercept)
Humira	(adalimumab)
Remicade	(infliximab)

Rheumatology (Psoriatic Arthritis)

Tier 1	
Cimzia	(certolizumab pegol)
Cosentyx	(secukinumab)
Inflixtra	(infliximab)
Simponi	(golimumab)
Tier 2	
Enbrel	(etanercept)
Humira	(adalimumab)
Remicade	(infliximab)

Rheumatology (Rheumatoid Arthritis)

Tier 1	
Actemra	(tocilizumab)
Brenzys	(etanercept)
Cimzia	(certolizumab pegol)
Erelzi	(etanercept)
Inflixtra	(infliximab)
Orencia	(abatacept)
Rituxan	(rituximab)
Simponi	(golimumab)
Simponi IV	(golimumab)
Xeljanz	(tofacitinib)
Tier 2	
Enbrel	(etanercept)
Humira	(adalimumab)
Kineret	(anakinra)
Remicade	(infliximab)